Company Overview
Snapshot
Founded in January 2009 by Cnaani Tzali and Sergei Shnizer, Carmel Diagnostics operates with 1–10 employees. The company has raised $6.94 million across five funding rounds and holds one patent.
Business overview
Carmel Diagnostics specializes in developing diagnostic methods for measuring oxidative stress in biological liquids, a key biomarker for health and disease. The company's core technology, thermochemiluminescence (TCL), is applied in its lead product, the Fertissimo TCL Analyzer. This noninvasive embryo selection system targets the in-vitro fertilization (IVF) market, aiming to improve pregnancy success rates and reduce multiple births. Carmel Diagnostics also explores applications in risk stratification for patients with congestive heart failure, operating within the Health Tech & Life Sciences sector, specifically in medical devices, diagnostics, and digital healthcare.
Strategic signal
In September 2022, Carmel Diagnostics highlighted the significance of oxidative stress in embryo selection for IVF, underscoring the potential of its technology to enhance fertility treatment outcomes. This emphasizes the company's focus on leveraging its diagnostic capabilities to address critical needs in reproductive health, signaling a commitment to advancing its lead product, the Fertissimo TCL Analyzer, within a high-growth market.
Company Intelligence Q&A
- What is Carmel Diagnostics' primary focus?
- Carmel Diagnostics focuses on measuring oxidative stress in biological liquids using thermochemiluminescence (TCL) technology, with its lead product, the Fertissimo TCL Analyzer, designed for embryo selection in in-vitro fertilization (IVF).
- When was Carmel Diagnostics founded?
- Carmel Diagnostics was founded in January 2009.
- Has Carmel Diagnostics received any grants?
- In July 2017, Carmel Diagnostics collaborated with Aran R&D to secure an undisclosed grant from EU Horizon 2020.
- What is the company's employee count?
- Carmel Diagnostics operates with 1–10 employees.